Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas

Blood

Volumn 97, Issue 5, 2001, Pages 1370-1377

  Timmerman, John M ^a   Caspar, Clemens B ^a   Lambert, Stacie L ^a   Syrengelas, Athanasia D ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; FEMALE; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; VIRUS RECOMBINANT;

EID: 0035283032     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1370     Document Type: Article

References (60)

1. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
2. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits
3. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1
4. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
5. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
6. Naive idiotype-specific CD4+ T cells and immuno-surveillance of B-cell tumors
7. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor, II: Characterization of anti-idiotypic CTL lines and clones
8. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes
9. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy
10. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
11. Idiotypic vaccination as a treatment for a B cell lymphoma
12. Immunotherapy of established murine B cell lymphoma: Combination of idiotype immunization and cyclophosphamide
13. Tumor-specific idiotype vaccines in the treatment of patients with B cell lymphoma: Long term results of a clinical trial
14. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
15. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immunological responses in 26 patients
16. Idiotypic DNA vaccines against B-cell lymphoma
17. DNA immunization induces protective immunity against B-cell lymphoma
18. A nine-amino acid peptide from IL-1β augments antitumor immune response induced by protein and DNA vaccines
19. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
20. Methods for construction of adenovirus vectors
21. Construction of a defective adenovirus vector expressing the pseudorabies virus glycoprotein gp50 and its use as a live vaccine
22. High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: Protection elicited in a murine model
23. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
24. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
25. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice
26. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin
27. Immune response to transgene-encoded proteins limit the stability of gene expression after injection of replication defective adenovirus vectors
28. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier
29. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy
30. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice
31. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
32. Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells
33. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin
34. The pathology and homing of a transplantable murine B cell leukemia (BCL1)
35. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
36. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5
37. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
38. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma
39. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro
40. Idiotype vaccination against murine B cell lymphoma: Inhibition of tumor immunity by free idio-type protein
41. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell mediated immunity
42. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular requirements for the full expression of antitumor immunity
43. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses
44. DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection
45. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
46. Linkage of foreign carrier protein to a self tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
47. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells
48. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants
49. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
50. Immunogenicity and antigen structure
51. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma: A study of hybridoma class switch variants
52. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: Implications for passive and active immunization
53. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
54. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
55. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses
56. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
57. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
58. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression
59. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
60. Enhanced CTL responses mediated by plasmid DNA immunogenes encoding costimulatory molecules and cytokines